IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies

IONTAS Limited and FairJourney Biologics S.A recently announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of action. Based on this approach, the company has developed a panel of therapeutic candidates.

SARS-CoV-2 virus enters the body as a result of the viral spike protein binding to the ACE2 protein on the surface of lung cells. This interaction is driven by a small region of the spike protein and the majority of antibodies currently undergoing clinical trial bind to this site. However, this site has changed in some of the emerging viral variants, reducing or abolishing the effect of some clinical candidates. Drug candidate antibodies developed by IONTAS to this same site have been shown to retain binding to the emerging variants.

An alternative approach for tackling variants is to target alternative regions of the virus that have a greater degree of conservation, making escape variants less likely. GSK/VIR Biotechnology recently announced a successful Phase 3 trial of such an antibody. VIR-7831 is an antibody that binds to a region of the spike protein, which is highly conserved between SARS-CoV-2 and SARS-CoV-1 (a distantly related virus responsible for the outbreak of Severe Acute Respiratory Syndrome in 2003). VIR-7831 has shown an 85% reduction in hospitalization and death during the COMET-ICE clinical trial. The partnership is now seeking Emergency use Authorization in the US and other regions.

A sub-set of the IONTAS antibodies, show a similar functionality to VIR-7831, by binding to sites conserved both in the recently emerging SARS-CoV-2 variants as well as to the more distantly related SARS-CoV-1 virus.

Dr John McCafferty, CSO at IONTAS, said “The first wave of antibody drugs for treating COVID-19 was focused on achieving maximal neutralization to the original SARS-CoV-2 strain first identified in Wuhan. This led many companies to a target site on the virus that is very effective for neutralization but also prone to genetic change. Second-generation drug candidates need to anticipate the emergence of new variants by targeting more conserved sites. IONTAS has identified drug candidates that neutralize by targeting conserved regions of the virus. We now seek partners to help develop these to better position the world in tackling this dreadful disease.”

IONTAS was recently integrated in the FairJourney Group, financed by Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare. IONTAS offers services for antibody discovery using Phage Display Technology and Mammalian Display. The innovative Mammalian Display platform enables full-length antibodies to be expressed in the context of a mammalian cell, thereby allowing selection based on function, stability, expression and developability. For more information, visit https://www.iontas.co.uk/.

FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. Founded in 2012 and headquartered in Porto, FairJourney has grown to over 90 highly technically skilled employees today. The Company operates a flexible, customer-oriented ‘one-stop shop’ approach to biologics development focused on quality, reliability and partnership. FairJourney has successfully completed more than 460 projects for over 70 customers across big pharma and leading biotech companies to date. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate. For more information, visit http://fjb.pt/.